Patient-Centered Research, Evidera, London, UK
Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Thorax. 2020 Sep;75(9):735-743. doi: 10.1136/thoraxjnl-2019-213974. Epub 2020 Jul 6.
A variety of maintenance inhaler therapies are available to treat asthma and COPD. Patient-centric treatment choices require understanding patient preferences for the alternative therapies.
A self-completed web-based discrete choice experiment was conducted to elicit patient preferences for inhaler device and medication attributes. Selection of attributes was informed by patient focus groups and literature review.
The discrete choice experiment was completed by 810 patients with asthma and 1147 patients with COPD. Patients with asthma most valued decreasing the onset of action from 30 to 5 min, followed by reducing yearly exacerbations from 3 to 1. Patients with COPD most and equally valued decreasing the onset of action from 30 to 5 min and reducing yearly exacerbations from 3 to 1. Both patients with asthma and patients with COPD were willing to accept an additional exacerbation in exchange for a 15 min decrease in onset of action and a longer onset of action in exchange for a lower risk of adverse effects from inhaled corticosteroids. Patients with asthma and COPD valued once-daily over twice-daily dosing, pressurised inhalers over dry powder inhalers and non-capsule priming over single-use capsules, although these attributes were not valued as highly as faster onset of action or reduced exacerbations.
The most important maintenance inhaler attributes for patients with asthma and COPD were fast onset of symptom relief and a lower rate of exacerbations. Concerns about safety of inhaled corticosteroids and device convenience also affected patient preferences but were less important.
有多种维持性吸入疗法可用于治疗哮喘和 COPD。以患者为中心的治疗选择需要了解患者对替代疗法的偏好。
通过自我完成的基于网络的离散选择实验,来确定患者对吸入装置和药物属性的偏好。属性的选择是基于患者焦点小组和文献回顾。
810 名哮喘患者和 1147 名 COPD 患者完成了离散选择实验。哮喘患者最看重的是将起效时间从 30 分钟缩短至 5 分钟,其次是将每年的恶化次数从 3 次减少至 1 次。COPD 患者最看重和同等看重的是将起效时间从 30 分钟缩短至 5 分钟,以及将每年的恶化次数从 3 次减少至 1 次。哮喘和 COPD 患者都愿意接受一次额外的恶化,以换取 15 分钟的起效时间缩短和更长的起效时间,以换取吸入皮质激素不良反应风险的降低。哮喘和 COPD 患者更看重每日一次的给药方案而不是每日两次,更看重压力型吸入器而不是干粉吸入器,更看重非胶囊预充而不是单次使用的胶囊,尽管这些属性的重要性不如起效更快或恶化减少那么高。
对于哮喘和 COPD 患者来说,最重要的维持性吸入器属性是快速缓解症状和降低恶化率。对吸入皮质激素安全性和设备便利性的担忧也影响了患者的偏好,但这些问题没有那么重要。